Affluent Medical, a French clinical-phase MedTech company specializing in the international development and industrialization of innovative medical prostheses, announces today that Gilbert Dupont – Société Générale Group has initiated coverage of its stock.
Gilbert Dupont – Société Générale Group began covering the stock with a study entitled “Un pour tous, tous pour un” (“one for all and all for one“), published on 3 April 2024. In this study, Gilbert Dupont – Société Générale Group recommended buying the stock, with a target price of €3.30, representing a potential upside of 89% compared with the closing price on 2 April 2024.
This initiation completes the coverage of Affluent Medical’s stock and adds to the financial analyst consensus alongside Invest Securities, Kepler Cheuvreux, Portzamparc BNP Paribas Group, and TP ICAP Midcap.
